<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210523051370N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-20</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of lavender on dialysis patients</public_title>
      <acronym></acronym>
      <scientific_title>The effect of different doses of lavender on the psychological states and physical fatigue in dialysis patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57284</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Patients will be selected based on systematic random sampling. Since about 140 patients are at the dialysis center every day, and the number of participants in each group is 40, the fixed periodic interval becomes 3 (140/40~3). Therefore, every third of the patients admitted to this center on Saturdays, Mondays, and Wednesdays are recruited into the experimental group, and the next one enters the control group-1. If any of these patients do not meet the inclusion criteria, the next one will be selected. If they do not meet the inclusion criteria, the previous one will be selected. Finally, 80 patients will be allocated to the experimental group and control group-1. Likewise, the number of patients referring to the center is 140 on Sundays, Tuesdays, and Thursdays. Since the number of required participants in the control group-2 is 40, every third patient will be selected, Blinding description: In this study, the assessor will be blinded to treatment allocation. To eliminate the effect of lavender fragrance on the assessor, a few drops of lavender essential oil will be splashed on the internal layer of their face mask.</study_design>
      <phase>N/A</phase>
      <hc_freetext>hemodialysis patients.</hc_freetext>
      <i_freetext>Intervention 1: Experimental group undergo inhalation of Lavender Angustifolia essential oil with herbarium number 1-133 procured from the Barij Essence Pharmaceutical Company (Kashan, Iran) and stored in semi-opaque UV-resistant glass bottles at room temperature. Lavender essential oil is inhaled on dialysis days for 5 weeks. A cotton ball soaked in two drops of lavender essential oil with concentrations of 10% in the first week (3 sessions), 20% in the second week (3 sessions), 30% in the third week (3 sessions), 40% in the fourth week (3 sessions) and 50% in the fifth week (3 sessions) will be attached to the collar at a distance of 10 cm from the patient's nose. Patient will be asked to breathe normally for 20 minutes. All patients will be in a semi-sitting position when inhaling lavender essential oil. Intervention 2: Control group 1: a cotton ball soaked in two drops of sweet almond oil is attached to the patients' collars at a distance of 10 cm from the nose. Intervention 3: Control group 2: a cotton ball soaked in two drops of sweet almond oil is attached to the patients' collars at a distance of 10 cm from the nose. The difference between the two control groups is the hemodialysis days. If these two control groups have outcomes that differ significantly, then this cannot reflect an effect of the treatment. The power of two control groups exceeds the probability of falsely detecting a treatment effect.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is All data will be kept confidential.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Seyed Afshin Shorofi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mazandaran University of Medical Sciences, Sari, Iran</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4816715793</zip>
        <telephone>+98 911 676 6280</telephone>
        <email>arabhoda1364@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Seyed Afshin Shrofi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mazandaran University of Medical Sciences, Sari, Iran</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۸۱۶۷۱۵۷۹۳</zip>
        <telephone>098 11 33367342</telephone>
        <email>ashorofi@yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18 years and older
Willingness to participate in the study
Undergoing dialysis three times a week
Ability to communicate
Absence of mental disorders
No experience of any stressful event in the last 6 months (such as the death of a close relative)
Not using sedatives
No history of hospitalization due to psychological problems
No history of drug and alcohol addiction
Dialysis treatment for a minimum of 6 months</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Kidney transplant candidates
Pregnancy or decision to become pregnant
Breastfeeding
History of allergies to essential oils and perfumes
Acute respiratory disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Experimental group undergo inhalation of Lavender Angustifolia essential oil with herbarium number 1-133 procured from the Barij Essence Pharmaceutical Company (Kashan, Iran) and stored in semi-opaque UV-resistant glass bottles at room temperature. Lavender essential oil is inhaled on dialysis days for 5 weeks. A cotton ball soaked in two drops of lavender essential oil with concentrations of 10% in the first week (3 sessions), 20% in the second week (3 sessions), 30% in the third week (3 sessions), 40% in the fourth week (3 sessions) and 50% in the fifth week (3 sessions) will be attached to the collar at a distance of 10 cm from the patient's nose. Patient will be asked to breathe normally for 20 minutes. All patients will be in a semi-sitting position when inhaling lavender essential oil.</i_keyword>
      <i_keyword>Control group 1: a cotton ball soaked in two drops of sweet almond oil is attached to the patients' collars at a distance of 10 cm from the nose.</i_keyword>
      <i_keyword>Control group 2: a cotton ball soaked in two drops of sweet almond oil is attached to the patients' collars at a distance of 10 cm from the nose. The difference between the two control groups is the hemodialysis days. If these two control groups have outcomes that differ significantly, then this cannot reflect an effect of the treatment. The power of two control groups exceeds the probability of falsely detecting a treatment effect.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety and depression. Timepoint: Before the intervention and the end of the first, second, third, fourth and fifth weeks. Method of measurement: The Hospital Anxiety and Depression Scale.</prim_outcome>
      <prim_outcome>Fatigue. Timepoint: Before the intervention and the end of the first, second, third, fourth and fifth weeks. Method of measurement: Fatigue Severity Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Wellbeing. Timepoint: Before the intervention and the end of the first, second, third, fourth and fifth weeks. Method of measurement: Visual Analog Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-03-25</approval_date>
        <contact_name>Bioethics Committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor (Research), Mazandaran University of Medical Sciences, Moallem Square, Sari, Iran Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
